Dan Teleman, CEO
Wayne M Dankner, MD, Chief Medical Officer
Esti Hayun, CFO
Mrs. Hayun joined Atox Bio in September 2014. Mrs. Hayun brings over 15 years of experience in both publicly traded and private companies. Prior to joining Atox Bio, Mrs. Hayun served as the CFO of Proteologics Ltd. (TASE: PRTL), a drug discovery company focusing on the Ubiquitin system from 2005 to 2013. Prior to Proteologics, Mrs. Hayun served as a Finance Manager in several companies, including Colbar LifeSiences Ltd., a Medical Device company.
Michele LaRussa, Chief Regulatory Officer
Corinne Zollmann, PhD, Senior VP CMC
Prior to joining Atox Bio in 2014, Dr. Zollmann was Senior Director of Chemistry, Manufacturing and Controls (CMC) at Chiasma. Prior to that, she served for over 20 years in numerous leadership positions at Teva Pharmaceutical’s Global Innovative R&D Division, and most recently, as Director of the CMC Program for Small Molecules. During this period she gained broad experience in global development of innovative pharmaceutical drug products, including CMC management and development, validation, technology transfer, regulatory strategy and initiatives, and professional CMC project evaluation and due diligence.
Meir Batito, VP Quality
Mr. Batito joined Atox Bio in 2016 with over 15 years of pharmaceutical experience. Prior to joining Atox Bio, Mr. Batito served as QA Senior Director at Teva Pharmaceuticals, leading one of the largest ‘site QA’ groups within the Teva network. Previously, he was Director of laboratories for Kamada Inc, where he led the quality control unit from pre-clinical stage to a successful FDA pre-approval inspection. Earlier in his career, Mr. Batito served as R&D researcher for Perrigo Israel Pharmaceuticals.
Elisa Foltz, VP Commercial
Ms. Foltz joined Atox Bio in January 2021 with more than 20 years of sales, marketing, and consulting experience in the pharmaceutical and biotech industries. Prior to joining Atox Bio, she was the VP, US Marketing at BioCryst Pharmaceuticals, a publicly-traded commercial-stage biotech company based in Durham, North Carolina. Ms. Foltz previously served as the Head of Marketing, North America at Ablynx and held multiple commercial positions of increasing responsibility at CSL Behring in the Philadelphia area. Her experience also includes Pfizer and several privately-held companies. During her professional career, Ms. Foltz has successfully led multiple rare disease and specialty product launches. She holds a B.S. degree in Biology from Virginia Tech and an M.B.A. from the University of Maryland, College Park.